Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: Discrepancy between published reports and community practice-a retrospective analysis

Current Oncology

Volumn 17, Issue 2, 2010, Pages 2-3

  Vandenberg, T ^a   Younus, J ^b   Al Khayyat, S ^b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b NONE

Author keywords

Adjuvant chemotherapy; Breast cancer; Febrile neutropenia

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; POPULATION RISK; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 77950589177     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i2.498     Document Type: Article

References (10)

1. Clarke M, Coates AS, Darby SC, et al. on behalf of the Early Breast Cancer Trialists' Collaborative Group (ebctcg). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29-40.
2. Muss HB, Woolf S, Berry D, et al. on behalf of the Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-81.
3. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
4. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of U.S. Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-83.
5. Cancer Care Ontario (cco) and Action Cancer Ontario (aco). Emergency department visits after adjuvant chemotherapy [Web page]. Toronto, ON: cco and aco; 2009. [Available at: csqi.cancercare.on.ca/cms/one.aspx?pageId=41148; cited August 18, 2009]
6. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors V.1.2010. Fort Washington, PA: nccn; 2010. [Available online at: www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf (registration required); cited February 19, 2010]
7. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. [Available online at: jco.ascopubs.org/cgi/reprint/24/19/3187; cited June 9, 2009]
8. Jones SE, Savin MA, Holmes FA, et al. Phase iii trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006:24:5381-7.
9. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009;27:2170-6.
10. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony- stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-11.